

CS/BSE/ AFR/BOOK-CL
May 14, 2013

TO
THE MANAGER
LISTING DEPARTMENT
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
EXCHANGE PLAZA, BANDRA KURLA COMPLEX
BANDRA (E), MUMBAI - 400 051

Dear Sir/Madam,

Stock Code – SUVEN

Sub: 1) Notification of Audited Financial Results for the financial year ended 31st March 2013 – Clause 41
2) Dividend Recommendation – Clause 20
3) Closure of Register of Members & Share Transfer Books - Clause-16

1) Notification of Audited Financial Results for the financial year ended 31st March 2013-Clause 41 and other information

We are forwarding herewith Audited Financial Results for the financial year 2012-2013, in the prescribed Proforma, as required under Clause-41 of the listing agreement as amended. The Board of Directors of our company has taken on record the enclosed Annual Audited financial results for the financial year 2012-2013 in its meeting held today i.e. 14th May, 2013 and Auditor's Report of the Company.

Brief Financials as required to be furnished under clause 20 are as follows:

(Rs in lakhs)

Particulars		2012-13	2011-12
(i).	Revenue from operations	25788.46	20420.78
(ii).	Operating expenditure	20469.90	18106.14
(iii).	Depreciation and amortization	786.72	599.79
(iv).	Operating profit	4531.84	1714.86
(v).	Interest expense	1350.94	990.93
(vi).	Other income	104.34	190.25
(vii).	Profit before Tax	3285.24	914.18
(viii).	Provision for Tax	201.29	(522.06)
(ix).	Profit for the year	3083.95	1436.24
(x).	Balance brought forward from previous year	3705.12	2825.93

Page | 1

Suven Life Sciences Limited

Regd. Office: Serene Chambers, Road # 5, Avenue 7, Banjara Hills, Hyderabad 500 034, INDIA

Tel: 91~40~2354 1142/ 3311/ 3315 Fax: 91~40~2354 1152

info@suven.com

www.suven.com

(xi).	Profit available for appropriation	6789.07	4262.17
	Appropriations:		
(xii).	Proposed final dividend	350.49	350.20
(xiii).	Tax on dividend	59.56	56.81
(xiv).	Difference in final dividend plus tax (10-11)	0.02	0.04
(xv).	Transfer to General Reserve	310.00	150.00
(xvi).	Balance carried to balance sheet	6069.00	3705.12

2) Dividend Recommendation – Clause 20

The Board of Directors in its meeting held today i.e. 14th May, 2013, has also recommended Dividend Re 30 paise per equity share of face value of Re 1/- each (30%) for the financial year ended 31/03/2013 the dividend will be paid on and from 27th August, 2013, subject to the approval of Members in the ensuing Annual General Meeting.

3) Closure of Register of Members & Share Transfer Books - Clause-16


Pursuant to clause 16 of the Listing agreement, we hereby notify the Book Closure dates for the Register of members and Share Transfer as under.

Security Code	Type of Security & Paid-up value	Book-Closure		Purpose
		From	To	
SUVEN	Equity Shares Rs 1.00 each	05/08/2013	07/08/2013	AGM & Dividend Declaration
		(both days inclusive)		

The Annual General Meeting of the Company will be held on Tuesday the 13th day of August 2013

Please find enclosed Press release of our company. We request you to take these documents on your records.

Thanking You,
Yours faithfully,
For **SUVEN LIFE SCIENCES LIMITED**


K HANUMANTHA RAO
Company Secretary






SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH 2013

PART - I		(₹ in lakhs), except share data				
Sl. No.	PARTICULARS	Quarter Ended			Year to date figures	Previous Year Ended
		31/03/2013	31/12/2012	31/03/2012	31/03/2013	31/03/2012
		Audited	Un-audited	Audited	Audited	Audited
1	Income from operations					
	(a) Net sales/income from operations (Net of excise duty)	7,470.36	6,239.48	6,289.42	25,788.46	20,420.78
	(b) Other operating income	-	-	-	-	-
	Total income from operations (net)	7,470.36	6,239.48	6,289.42	25,788.46	20,420.78
2	Expenses					
	a) Cost of materials consumed	2,634.47	2,364.64	2,487.22	8,827.40	8,145.56
	b) Purchases of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	185.25	(773.81)	418.09	(559.63)	(564.74)
	d) Employee benefits expense	554.62	768.53	633.69	2,537.70	2,283.03
	e) Depreciation and amortisation expense	214.43	219.01	182.78	786.72	599.79
	f) Other expenses - Manufacturing Exps	1,147.76	1,014.79	791.31	3,904.81	2,667.83
	- Selling Exps	223.65	95.36	43.86	502.80	216.91
	- Administrative Exps	409.34	264.22	446.39	1,787.50	1,704.57
	- R & D Exps	982.12	929.72	821.77	3,469.32	3,304.91
	- Provision for MTM on Forward contracts	(26.07)	89.38	(854.63)	-	348.06
	Total expenses	6,325.57	4,971.84	4,970.48	21,256.62	18,705.92
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	1,144.79	1,267.64	1,318.94	4,531.84	1,714.86
4	Other Income	54.29	36.84	(148.59)	104.34	190.25
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	1,199.08	1,304.48	1,170.35	4,636.18	1,905.11
6	Finance costs	270.74	468.53	420.86	1,350.94	990.93
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	928.34	835.95	749.49	3,285.24	914.18
8	Exceptional Items	-	-	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7 ± 8)	928.34	835.95	749.49	3,285.24	914.18
10	Tax Expenses	65.30	60.27	34.91	201.29	(522.06)
11	Net Profit/ (Loss) from Ordinary Activities after tax (9 ± 10)	863.04	775.68	714.58	3,083.95	1,436.24
12	Extraordinary Items (net of tax expense ₹ ____ Lakhs)	-	-	-	-	-
13	Net Profit (+)/Loss(-) for the period (11 ± 12)	863.04	775.68	714.58	3,083.95	1,436.24
14	Share of profit / (loss) of associates*	-	-	-	-	-
15	Minority interest *	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15) *					
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	1,168.29 Re. 1.00	1,167.32 Re. 1.00	1,167.32 Re. 1.00	1,168.29 Re. 1.00	1,167.32 Re. 1.00
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	14,277.69	11,584.83
19.i	Earning Per Share (EPS) (before extraordinary items) (of ₹ Rs.1/- each) (not annualised):					
	a) Basic	0.74	0.66	0.61	2.64	1.23
	b) Diluted	0.74	0.66	0.61	2.64	1.23
19.ii	Earning Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):					
	a) Basic	0.74	0.66	0.61	2.64	1.23
	b) Diluted	0.74	0.66	0.61	2.64	1.23



PART - II		31/03/2013	31/12/2012	31/03/2012	31/03/2013	31/03/2012
A	PARTICULARS OF SHAREHOLDING	Audited	Un-audited	Audited	Audited	Audited
1	Public share holdings - Number of shares - Percentage of Share holding	41,993,960 35.94%	42,679,160 36.56%	42,679,160 36.56%	41,993,960 35.94%	42,679,160 36.56%
2	Promoters and promoter group Shareholding**					
a)	Pledged / Encumbered	NIL	NIL	NIL	NIL	NIL
	- Number of shares					
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL
b)	Non-Encumbered	74,834,828	74,052,828	74,052,828	74,834,828	74,052,828
	- Number of shares					
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	64.06%	63.44%	63.44%	64.06%	63.44%
Particulars		3 months ended (31/03/2013)				
B	INVESTOR COMPLAINTS					
	Pending at the beginning of the quarter	0				
	Received during the quarter	27				
	Disposed of during the quarter	27				
	Remaining unresolved at the end of the quarter	0				

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED						Rs.in Lacs
PARTICULARS	Quarter Ended			Year to date figures		Year Ended
	31/03/2013	31/12/2012	31/03/2012	31/03/2013	31/03/2012	31/03/2012
	Audited	Un-audited	Audited	Audited	Audited	Audited
1	SEGMENT REVENUE :-					
a)	Manufacturing (CRAMS)	6,484.41	5,402.01	5,893.92	22,760.54	19,168.87
b)	Services	985.96	837.46	367.88	3,027.92	1,251.91
c)	Research & Development	-	-	-	-	-
	Net Sales from Operations	7,470.37	6,239.47	6,261.80	25,788.46	20,420.78
2	SEGMENT RESULTS :-					
	Profit/(Loss) before tax and interest:					
a)	Manufacturing (CRAMS)	2,112.34	1,904.71	1,708.87	7,928.86	6,507.91
b)	Services	258.94	618.02	72.38	1,514.45	531.83
c)	Research & Development	(982.12)	(929.72)	(821.77)	(3,469.32)	(3,304.91)
	TOTAL	1,389.16	1,593.01	959.48	5,973.99	3,734.83
Less: i)	Interest	172.97	441.82	318.43	1,174.34	888.50
ii)	Other Un-allocable exps net off un-allocable Income	287.84	315.24	(106.44)	1,514.40	1,932.15
	Total Profit Before Tax	928.35	835.95	749.49	3,285.25	914.18
3	CAPITAL EMPLOYED					
	(Segment Assets - Segment Liabilities)					
a)	Manufacturing (CRAMS)	12,823.28	13,053.17	10,704.10	12,823.28	10,704.10
b)	Services	3,053.52	3,035.70	3,298.34	3,053.52	3,298.34
c)	Research & Development	2,412.64	2,157.59	2,228.26	2,412.64	2,228.26
d)	Net assets which are not segmented and used commonly	3,574.87	4,237.93	2,023.90	3,574.87	2,023.90
	TOTAL	21,864.31	22,484.39	18,254.60	21,864.31	18,254.60

Notes: 1) The above audited results were approved and taken on record at the Board of Directors' meeting held on 14th May '13

2) Previous years figures have been regrouped / reclassified whenever necessary.

3) The figures of the last quarter are the balancing figures between audited figures in respect of full year and un-audited declared upto 3rd quarter ending.

4) Suven Nishta Pharma Pvt Ltd, the 100% subsidiary, has been merged w.e.f. 1st Jan 2012. Hence the current year's figures are not comparable with the previous year figures.

5) The Board has recommended a Dividend of Re.0.30 per Equity share (i.e.30% of face value of Rs.1/- each) for the year 2012-13, subject to approval of the shareholders in the ensuing Annual General Meeting.

Place: Hyderabad
Date: 14th May 2013



For SUVEN LIFE SCIENCES LTD

VENKAT JASTI
Chairman & CEO

We Deliver



SUVEN LIFE SCIENCES LTD


Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

Standalone Statement of Assets & Liabilities as per Clause 41(V)(h) as per Listing agreement

(Rs. In lakhs)

	Particulars	Year ended	
		31/03/2013	31/03/2012
A	EQUITY AND LIABILITIES		
1	Shareholder's funds:		
	(a) Share Capital	1,168.29	1,167.32
	(b) Reserves and Surplus	14,277.69	11,584.83
	Sub-total - Shareholders' funds	15,445.98	12,752.15
2	Non-current liabilities		
	(a) Long-term borrowings	6,418.33	5,502.45
	(d) Long-term provisions	157.78	178.35
	Sub-total - Non-current liabilities	6,576.11	5,680.80
3	Current liabilities		
	(a) Short-term borrowings	2,782.59	2,285.40
	(b) Trade payables	3,613.53	2,511.07
	(c) Other current liabilities	3,611.53	4,020.81
	(d) Short-term provisions	1,382.72	1,248.50
	Sub-total - Current liabilities	11,390.37	10,065.78
	TOTAL - EQUITY AND LIABILITIES	33,412.46	28,498.73
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	16,566.30	15,608.37
	(b) Non-current investments	0.15	0.10
	(c) Deferred tax assets (net)	1,569.62	1,760.96
	(d) Long-term loans and advances	943.83	644.44
	Sub-total - Non-current assets	19,079.90	18,013.87
2	Current assets		
	(a) Current investments	7.12	452.33
	(b) Inventories	5,381.43	4,650.17
	(c) Trade receivables	2,377.76	2,523.93
	(d) Cash and cash equivalents	2,178.69	316.87
	(e) Short-term loans and advances	4,367.88	2,528.88
	(f) Other current assets	19.68	12.68
	Sub-total - Current assets	14,332.56	10,484.86
	TOTAL - ASSETS	33,412.46	28,498.73

For Suven Life Sciences Ltd



Venkat Jasti
Chairman & CEO



**Auditor's Report On Quarterly Financial Results and Year to Date Results of
M/s Suven Life Sciences Limited Pursuant to the Clause 41 of the Listing Agreement**

To
Board of Directors of M/s. Suven Life Sciences Limited

We have audited the quarterly financial results of M/s Suven Life Sciences Limited for the quarter ended 31st March, 2013 and the year to date results for the period 1st April, 2012 to 31st March, 2013, attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per Section 211(3C) of the Companies Act, 1956 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31st March, 2013 as well as the year to date results for the period from 1st April 2012 to 31st March 2013.


Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For KARVY & CO.

Chartered Accountants

Firm's registration number: 01757S

(K. AJAY KUMAR)
PARTNER
(M. No. 021989)



Place: Hyderabad

Date: 14-05-2013

News Release

Suven's PAT up by 115% for the year ended Mar 2013

HYDERABAD, INDIA (14 May' 2013) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its audited financial results for the quarter and year ended 31st Mar 2013. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th May 2013 at Hyderabad.

Financial Highlights for the 4th Quarter ended Mar' 2013:

Growth in revenue	Rs 747 Mn vs. Rs 629 Mn	-	Up by 23%
Growth in PAT	Rs. 86 Mn vs. Rs 71 Mn	-	Up by 21%
Growth in EBIDTA	Rs 141 Mn vs. Rs 135 Mn	-	Up by 4%

Financial Highlights for the year ended Mar' 2013:

Growth in revenue	Rs. 2579 Mn vs. Rs 2042 Mn	-	Up by 26%
Growth in PAT	Rs. 308 Mn vs. Rs 144 Mn	-	Up by 115%
Growth in EBIDTA	Rs. 542 Mn vs. Rs 250 Mn	-	Up by 117%

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 347 Mn (13.4% on revenue) for the year ended Mar' 2013.

The Board has recommended a Dividend of Re 0.30 per share (30% of face value of Rs.1.00 each) for the accounting year 2012-13 subject to the approval in AGM.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;



SUVEN LIFE SCIENCES LIMITED

Regd. Office: SDE Serene Chambers | Road No.5 | Avenue 7 | Banjara Hills | Hyderabad – 500 034 | India
Tel: 91 40 2354 1142/3311 Fax: 91 40 2354 1152 Email: info@suven.com , www.suven.com